New England Journal of Medicine, volume 390, issue 6, pages 497-509

A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

Stephen A. Harrison ¹

Pierre Bedossa ¹

Cynthia D. Guy ¹

Jörn M. Schattenberg ¹

Rohit Loomba ¹

Rebecca Taub ¹

Dominic Labriola ¹

Sam E. Moussa ¹

Guy W Neff ¹

Mary E. Rinella ¹

Quentin M Anstee ¹

Manal F. Abdelmalek ¹

Zobair M Younossi ¹

Seth J Baum ¹

Sven Francque ¹

Michael R. Charlton ¹

Philip N Newsome ¹

Nicolas Lanthier ¹

Ingolf Schiefke ¹

Alessandra Mangia ¹

Juan M. Pericàs ¹

Rashmee Patil ¹

Arun J. Sanyal ¹

Mazen Noureddin ¹

Meena B Bansal ¹

Naim Alkhouri ¹

Laurent Castera ¹

Madhavi Rudraraju ¹

Vlad Ratziu ¹

Show full list: 29 authors

Hide authors affiliations Show authors affiliations: 1 affiliation

From the University of Oxford, Oxford (S.A.H.), the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne (Q.M.A.), and the National Institute for Health Research, Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, Birmingham (P.N.N.) — all in the United Kingdom; Pinnacle Clinical Research, San Antonio (S.A.H., M.R.), South Texas Research Institute, Edinburg (R.P.), and...

University of Oxford

University Hospitals Birmingham NHS Foundation Trust

Newcastle University

Publication type: Journal Article

Publication date: 2024-02-08

Massachusetts Medical Society

Journal: New England Journal of Medicine

scimago Q1

SJR: 20.544

CiteScore: 145.4

Impact factor: 96.2

ISSN: 00284793, 15334406

DOI: 10.1056/nejmoa2309000

Copy DOI

General Medicine

Found

Top-30

Journals

	2 4 6 8 10 12 14 16 18
Journal of Hepatology	Journal of Hepatology, 17, 3.02% Journal of Hepatology 17 publications, 3.02%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 15, 2.67% International Journal of Molecular Sciences 15 publications, 2.67%
Nature Reviews Gastroenterology and Hepatology	Nature Reviews Gastroenterology and Hepatology, 14, 2.49% Nature Reviews Gastroenterology and Hepatology 14 publications, 2.49%
Liver International	Liver International, 14, 2.49% Liver International 14 publications, 2.49%
Metabolism: Clinical and Experimental	Metabolism: Clinical and Experimental, 13, 2.31% Metabolism: Clinical and Experimental 13 publications, 2.31%
Hepatology	Hepatology, 13, 2.31% Hepatology 13 publications, 2.31%
Alimentary Pharmacology and Therapeutics	Alimentary Pharmacology and Therapeutics, 12, 2.14% Alimentary Pharmacology and Therapeutics 12 publications, 2.14%
JHEP Reports	JHEP Reports, 9, 1.6% JHEP Reports 9 publications, 1.6%
Hepatology Communications	Hepatology Communications, 8, 1.42% Hepatology Communications 8 publications, 1.42%
Biomedicines	Biomedicines, 7, 1.25% Biomedicines 7 publications, 1.25%
Scientific Reports	Scientific Reports, 7, 1.25% Scientific Reports 7 publications, 1.25%
Nutrients	Nutrients, 6, 1.07% Nutrients 6 publications, 1.07%
New England Journal of Medicine	New England Journal of Medicine, 5, 0.89% New England Journal of Medicine 5 publications, 0.89%
Liver Research	Liver Research, 5, 0.89% Liver Research 5 publications, 0.89%
Journal of Clinical Medicine	Journal of Clinical Medicine, 5, 0.89% Journal of Clinical Medicine 5 publications, 0.89%
Metabolism and Target Organ Damage	Metabolism and Target Organ Damage, 5, 0.89% Metabolism and Target Organ Damage 5 publications, 0.89%
Cell Metabolism	Cell Metabolism, 5, 0.89% Cell Metabolism 5 publications, 0.89%
The Lancet Gastroenterology and Hepatology	The Lancet Gastroenterology and Hepatology, 5, 0.89% The Lancet Gastroenterology and Hepatology 5 publications, 0.89%
Frontiers in Pharmacology	Frontiers in Pharmacology, 5, 0.89% Frontiers in Pharmacology 5 publications, 0.89%
Biomolecules	Biomolecules, 5, 0.89% Biomolecules 5 publications, 0.89%
Clinical Gastroenterology and Hepatology	Clinical Gastroenterology and Hepatology, 5, 0.89% Clinical Gastroenterology and Hepatology 5 publications, 0.89%
Cureus	Cureus, 5, 0.89% Cureus 5 publications, 0.89%
Lipids in Health and Disease	Lipids in Health and Disease, 4, 0.71% Lipids in Health and Disease 4 publications, 0.71%
Nature Metabolism	Nature Metabolism, 4, 0.71% Nature Metabolism 4 publications, 0.71%
Clinics and Research in Hepatology and Gastroenterology	Clinics and Research in Hepatology and Gastroenterology, 4, 0.71% Clinics and Research in Hepatology and Gastroenterology 4 publications, 0.71%
Expert Opinion on Pharmacotherapy	Expert Opinion on Pharmacotherapy, 4, 0.71% Expert Opinion on Pharmacotherapy 4 publications, 0.71%
Journal of Medicinal Chemistry	Journal of Medicinal Chemistry, 4, 0.71% Journal of Medicinal Chemistry 4 publications, 0.71%
Antioxidants	Antioxidants, 4, 0.71% Antioxidants 4 publications, 0.71%
World Journal of Gastroenterology	World Journal of Gastroenterology, 4, 0.71% World Journal of Gastroenterology 4 publications, 0.71%
	2 4 6 8 10 12 14 16 18

Publishers

	20 40 60 80 100 120 140 160 180
Elsevier	Elsevier, 169, 30.07% Elsevier 169 publications, 30.07%
Springer Nature	Springer Nature, 101, 17.97% Springer Nature 101 publications, 17.97%
MDPI	MDPI, 62, 11.03% MDPI 62 publications, 11.03%
Wiley	Wiley, 55, 9.79% Wiley 55 publications, 9.79%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 36, 6.41% Ovid Technologies (Wolters Kluwer Health) 36 publications, 6.41%
Cold Spring Harbor Laboratory	Cold Spring Harbor Laboratory, 20, 3.56% Cold Spring Harbor Laboratory 20 publications, 3.56%
Frontiers Media S.A.	Frontiers Media S.A., 19, 3.38% Frontiers Media S.A. 19 publications, 3.38%
Taylor & Francis	Taylor & Francis, 18, 3.2% Taylor & Francis 18 publications, 3.2%
Baishideng Publishing Group	Baishideng Publishing Group, 8, 1.42% Baishideng Publishing Group 8 publications, 1.42%
Georg Thieme Verlag KG	Georg Thieme Verlag KG, 7, 1.25% Georg Thieme Verlag KG 7 publications, 1.25%
Massachusetts Medical Society	Massachusetts Medical Society, 6, 1.07% Massachusetts Medical Society 6 publications, 1.07%
Oxford University Press	Oxford University Press, 6, 1.07% Oxford University Press 6 publications, 1.07%
BMJ	BMJ, 6, 1.07% BMJ 6 publications, 1.07%
OAE Publishing Inc.	OAE Publishing Inc., 5, 0.89% OAE Publishing Inc. 5 publications, 0.89%
American Chemical Society (ACS)	American Chemical Society (ACS), 5, 0.89% American Chemical Society (ACS) 5 publications, 0.89%
The Endocrine Society	The Endocrine Society, 4, 0.71% The Endocrine Society 4 publications, 0.71%
S. Karger AG	S. Karger AG, 3, 0.53% S. Karger AG 3 publications, 0.53%
SAGE	SAGE, 3, 0.53% SAGE 3 publications, 0.53%
Mary Ann Liebert	Mary Ann Liebert, 3, 0.53% Mary Ann Liebert 3 publications, 0.53%
American Medical Association (AMA)	American Medical Association (AMA), 3, 0.53% American Medical Association (AMA) 3 publications, 0.53%
Radiological Society of North America (RSNA)	Radiological Society of North America (RSNA), 2, 0.36% Radiological Society of North America (RSNA) 2 publications, 0.36%
American Association for the Advancement of Science (AAAS)	American Association for the Advancement of Science (AAAS), 2, 0.36% American Association for the Advancement of Science (AAAS) 2 publications, 0.36%
Walter de Gruyter	Walter de Gruyter, 2, 0.36% Walter de Gruyter 2 publications, 0.36%
Japan Society of Hepatology	Japan Society of Hepatology, 2, 0.36% Japan Society of Hepatology 2 publications, 0.36%
University of Toronto Press Inc. (UTPress)	University of Toronto Press Inc. (UTPress), 1, 0.18% University of Toronto Press Inc. (UTPress) 1 publication, 0.18%
American Society for Clinical Investigation	American Society for Clinical Investigation, 1, 0.18% American Society for Clinical Investigation 1 publication, 0.18%
Bioscientifica	Bioscientifica, 1, 0.18% Bioscientifica 1 publication, 0.18%
Medknow	Medknow, 1, 0.18% Medknow 1 publication, 0.18%
Royal Society of Chemistry (RSC)	Royal Society of Chemistry (RSC), 1, 0.18% Royal Society of Chemistry (RSC) 1 publication, 0.18%
Public Library of Science (PLoS)	Public Library of Science (PLoS), 1, 0.18% Public Library of Science (PLoS) 1 publication, 0.18%
	20 40 60 80 100 120 140 160 180

We do not take into account publications without a DOI.
Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

n/a Field Citation Ratio

n/a Relative Citation Ratio

Cite this

GOST |

Cite this

GOST Copy

Harrison S. A. et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis // New England Journal of Medicine. 2024. Vol. 390. No. 6. pp. 497-509.

GOST all authors (up to 50) Copy

Harrison S. A., Bedossa P., Guy C. D., Schattenberg J. M., Loomba R., Taub R., Labriola D., Moussa S. E., Neff G. W., Rinella M. E., Anstee Q. M., Abdelmalek M. F., Younossi Z. M., Baum S. J., Francque S., Charlton M. R., Newsome P. N., Lanthier N., Schiefke I., Mangia A., Pericàs J. M., Patil R., Sanyal A. J., Noureddin M., Bansal M. B., Alkhouri N., Castera L., Rudraraju M., Ratziu V. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis // New England Journal of Medicine. 2024. Vol. 390. No. 6. pp. 497-509.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1056/nejmoa2309000

UR - https://doi.org/10.1056/nejmoa2309000

TI - A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

T2 - New England Journal of Medicine

AU - Harrison, Stephen A.

AU - Bedossa, Pierre

AU - Guy, Cynthia D.

AU - Schattenberg, Jörn M.

AU - Loomba, Rohit

AU - Taub, Rebecca

AU - Labriola, Dominic

AU - Moussa, Sam E.

AU - Neff, Guy W

AU - Rinella, Mary E.

AU - Anstee, Quentin M

AU - Abdelmalek, Manal F.

AU - Younossi, Zobair M

AU - Baum, Seth J

AU - Francque, Sven

AU - Charlton, Michael R.

AU - Newsome, Philip N

AU - Lanthier, Nicolas

AU - Schiefke, Ingolf

AU - Mangia, Alessandra

AU - Pericàs, Juan M.

AU - Patil, Rashmee

AU - Sanyal, Arun J.

AU - Noureddin, Mazen

AU - Bansal, Meena B

AU - Alkhouri, Naim

AU - Castera, Laurent

AU - Rudraraju, Madhavi

AU - Ratziu, Vlad

PY - 2024

DA - 2024/02/08

PB - Massachusetts Medical Society

SP - 497-509

IS - 6

VL - 390

SN - 0028-4793

SN - 1533-4406

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2024_Harrison,

author = {Stephen A. Harrison and Pierre Bedossa and Cynthia D. Guy and Jörn M. Schattenberg and Rohit Loomba and Rebecca Taub and Dominic Labriola and Sam E. Moussa and Guy W Neff and Mary E. Rinella and Quentin M Anstee and Manal F. Abdelmalek and Zobair M Younossi and Seth J Baum and Sven Francque and Michael R. Charlton and Philip N Newsome and Nicolas Lanthier and Ingolf Schiefke and Alessandra Mangia and Juan M. Pericàs and Rashmee Patil and Arun J. Sanyal and Mazen Noureddin and Meena B Bansal and Naim Alkhouri and Laurent Castera and Madhavi Rudraraju and Vlad Ratziu},

title = {A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis},

journal = {New England Journal of Medicine},

year = {2024},

volume = {390},

publisher = {Massachusetts Medical Society},

month = {feb},

url = {https://doi.org/10.1056/nejmoa2309000},

number = {6},

pages = {497--509},

doi = {10.1056/nejmoa2309000}

}

MLA

Cite this

MLA Copy

Harrison, Stephen A., et al. “A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.” New England Journal of Medicine, vol. 390, no. 6, Feb. 2024, pp. 497-509. https://doi.org/10.1056/nejmoa2309000.

Found error?

Message

Support chat

Publisher

Massachusetts Medical Society

Journal

New England Journal of Medicine

scimago Q1

SJR

20.544

CiteScore

145.4

Impact factor

96.2

ISSN

00284793

15334406

Profiles

Schattenberg, Jörn M